Effect of Enalapril in Subjects With Hypertension Associated With Moderate to Severe Renal Dysfunction

Reams, Garry P.; Bauer, John H.

doi:10.1001/archinte.1986.00360230061010

Cited by 78 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GFR is less affected so the diffusion gradient for protein filtration and filtration fraction decreases. 16 Moreover, captopril could influence the permeability of the glomerular capillary wall. Recent data by Millner and Morgenstern showed that ACE inhibitors had also changed the size selective properties of the glomerular basement membrane.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of captopril treatment in children with steroid‐resistant nephrotic syndrome

Türkdoğan-Sözüer

Emre

Tanman

et al. 1994

Pediatrics International

View full text Add to dashboard Cite

We studied the efficacy of captopril, an angiotensin‐converting enzyme inhibitor in treating persistent moderate or severe proteinuria in children with various glomerular diseases other than minimal‐change nephrotic syndrome. Captopril was administered for 3 months to 15 normotensive and nonazotemic or mildly azotemic patients (12 boys, 3 girls) in whom corticosteroid and cytotoxic treatment had failed to induce remission. Urinary protein excretion decreased from 2873.14±1937.50 (mean ± s.e.m.) to 1684.71 ± 1463.13 mg/day (P < 0.05). The reduction in proteinuria was not related to a significant fall in systemic blood pressure or a change in renal function. Serum albumin did not rise and side effects due to captopril were not observed. We concluded that, in the short term, captopril can be used safely and effectively for decreasing the proteinuria of nephrotic children unresponsive to conventional therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of captopril treatment in children with steroid‐resistant nephrotic syndrome

Türkdoğan-Sözüer

Emre

Tanman

et al. 1994

Pediatrics International

View full text Add to dashboard Cite

show abstract

“…As previously mentioned, MR activation concurs in the pathophysiology of CKD [ 36 ], and aldosterone is supposed to be one among main actors. Aldosterone levels were shown to start to increase when the glomerular filtration rate (GFR) is reduced by 50% [ 37 ] and another study showed that aldosterone levels are elevated up to fourfold in patients with a mean GFR of 27 mL/min per 1.73 m 2 [ 38 ]. Additionally, during long-term blockade of the renin-angiotensin system (RAS), aldosterone breakthrough is seen [ 39 ].…”

Section: Finerenone: Why Another Mra?mentioning

confidence: 99%

Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist

Lullo

Lavalle

Scatena

et al. 2023

JCM

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is one of the most common complications of diabetes mellitus and an independent risk factor for cardiovascular disease. Despite guideline-directed therapy of CKD in patients with type 2 diabetes, the risk of renal failure and cardiovascular events still remains high, and diabetes remains the leading cause of end-stage kidney disease in affected patients. To date, current medications for CKD and type 2 diabetes mellitus have not reset residual risk in patients due to a high grade of inflammation and fibrosis contributing to kidney and heart disease. This question-and-answer-based review will discuss the pharmacological and clinical differences between finerenone and other mineralocorticoid receptor antagonists and then move on to the main evidence in the cardiovascular and renal fields, closing, finally, on the potential role of therapeutic combination with sodium-glucose cotransporter 2 inhibitors (SGLT2is).

show abstract

“…It is important to note that MR blockers (spironolactone, eplerenone) reduce proteinuria and progression of CKD very eff ectively, and independent of blood pressure reduction [ 18 , 42 ] . Also ACE inhibitors lower aldosterone and proteinuria in renal disease [ 56 ] , and should be considered as additional renoprotective therapy. An important, often underestimated factor in therapy of hypertension and PHA is the salt intake.…”

Section: Therapeutic Eff Ects In Phamentioning

confidence: 99%

Aldosterone and the Kidney

et al. 2011

View full text Add to dashboard Cite

The mineralocorticoid aldosterone is a key regulator of blood pressure, fluid and electrolyte homeostasis, and acts via the mineralocorticoid receptor (MR). In recent years, an increasing number of studies revealed deleterious effects of aldosterone via its receptor. Especially in patients with primary hyperaldosteronism (PHA) a significant higher risk of developing cardiovascular comorbidities and comortalities was reported. Also renal insufficiency is clearly increased in patients with PHA indicating a role of aldosterone and the MR in the pathogenesis of renal injury. It has been shown that aldosterone in combination with an elevated salt intake, leads to renal inflammation, fibrosis, podocyte injury, and mesangial cell proliferation. This review focuses on the current knowledge of aldosterone effects in the kidney and highlights this topic from 2 perspectives: from clinical medicine and from experimental studies.

show abstract

Effect of Enalapril in Subjects With Hypertension Associated With Moderate to Severe Renal Dysfunction

Cited by 78 publications

References 47 publications

Efficacy of captopril treatment in children with steroid‐resistant nephrotic syndrome

Efficacy of captopril treatment in children with steroid‐resistant nephrotic syndrome

Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist

Aldosterone and the Kidney

Contact Info

Product

Resources

About